---
title: "Insilico Medicine climbs 6%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304786592.md"
description: "Insilico Medicine rose 6.09% to HK$39.74. Down 38.32% over six months and up 6.79% YTD."
datetime: "2026-11-09T02:05:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304786592.md)
  - [en](https://longbridge.com/en/news/304786592.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304786592.md)
generator: "portal-rs"
---

# Insilico Medicine climbs 6%

Insilico Medicine (3696.HK) climbed more than **6%** in Hong Kong trading to **HK$39.74**.

The stock is up 8.66% over the past ten sessions, down 38.32% over the past six months and up 6.79% year to date. It sits 32.56% above its 52-week low of HK$29.98.

The Hang Seng Index is up 5.39% over the past five sessions and down 3.81% year to date.

The life sciences tools and services industry index rose 3.7% over the same period.

The company plans to invest about 303 million yuan to co-establish a biopharmaceutical investment fund with a target size of 1.01 billion yuan, focusing on growth-stage companies in biomedicine, life sciences and artificial intelligence.

Separately, Insilico announced a share buyback program of up to HK$500 million in the open market, noting that it believes the current share price undervalues its intrinsic value. Phase I clinical data for its AI-designed drug ISM6331, presented at the ESMO congress, showed an objective response rate of 40% in the 130mg mesothelioma cohort.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [03696.HK](https://longbridge.com/en/quote/03696.HK.md)

## Related News & Research

- [Insilico Medicine Subsidiary Partners With Luoxin Pharmaceuticals on AI-Powered Drug Discovery](https://longbridge.com/en/news/305433887.md)
- [INSILICO Plans Share Buyback of Up to HKD500M](https://longbridge.com/en/news/303654455.md)
- [Chainfir Capital says AI drug deal headlines mask reliance on uncertain milestone payments](https://longbridge.com/en/news/302495363.md)
- [InSilico Medicine Hits Early AI Drug Discovery Milestone in Servier Collaboration](https://longbridge.com/en/news/302341377.md)
- [Insilico Medicine Reports 40% Response Rate at 130 mg for ISM6331 in Phase 1 Mesothelioma Trial](https://longbridge.com/en/news/303086760.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**